Earnings Estimate Revisions for Durect For the fiscal year ending December 2024, this specialty pharmaceutical company is expected to earn -$0.50 per share, which is a change of 68.2% from the ...

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial DURECT Corporation (www.durect.com ...

Stock analysts at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the specialty ...

After Nektar’s mauling it was Durect’s turn to face the panel with its POSIMIR (bupivacaine extended-release solution), an investigational post-operative pain relief depot product. Posimir is ...

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated ...

CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th ...

What Are the BATMMAAN Stocks? If you're ready to move beyond Magnificent Seven stocks, there's a new acronym on Wall Street with one key addition.

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 80 points on Wednesday The Dow traded down 0.23% to 34,074.30 while the NASDAQ fell 0.01% to 13,638.07.

DURECT has a 1-year low of $0.68 and a 1-year high of $1.88. Institutional Investors Weigh In On DURECT An institutional investor recently raised its position in DURECT stock.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...